Cerus Corp (CERS) Stock Analysis and Metrics

Cerus

NASDAQ: CERS

$3.11 ▲ +0.18 (+6.14%)

At close: Jul 27, 2026 · 3:04 PM UTC

Financial Ratios

Market Cap602.81 Mn

P/E-63.01

P/S3.10

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)84.83 Mn

Revenue Growth (1y) (Qtr)24.10

Add ratio to table…

About

Cerus Corp is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, based on proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. It is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex, or IFC, and pathogen reduced plasma, cryoprecipitate reduced.

Cerus Corp generates revenue primarily through the sale of the INTERCEPT Blood System for platelets and plasma, including disposable kits and related components, sold via direct sales force and distributors. The company also sells IFC or disposable kits to manufacture IFC in the U. S. using its direct sales force. Revenue is derived from commercial sales of pathogen-reduced blood products and associated technologies to blood centers, hospitals, and other healthcare providers globally.

Cerus Corp operates through the following segments:

• INTERCEPT Blood System—Platelets: This segment provides pathogen reduction technology for apheresis platelet components collected and stored in 100% plasma or InterSol to reduce the risk of transfusion-transmitted infection, including sepsis, and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease. The platelet system received CE Certificate of Conformity and CE Marked under MDR in 2023 and is commercialized in the U. S., Canada and a number of countries in Europe, the CIS, the Middle East, and selected countries in other regions around the world. The FDA has approved the platelet system for ex vivo preparation of pathogen-reduced apheresis platelet components.

• INTERCEPT Blood System—Plasma: This segment provides pathogen reduction technology for plasma to reduce the risk of transfusion-transmitted infection when treating patients requiring therapeutic plasma transfusion and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease. The plasma system received CE Certificate of Conformity and CE Marked under MDR in 2023 and is commercialized in the U. S. and a number of countries in Europe, the CIS, the Middle East, and selected countries in other regions around the world. The company received FDA approval of the premarket approval supplement, or PMA, to produce IFC in 2020.

• INTERCEPT Blood System—Red Blood Cells: This segment is designed to inactivate blood-borne pathogens in red blood cells intended for transfusion using the proprietary compound amustaline. The red blood cell system is currently in development and has not been commercialized anywhere in the world, with ongoing Phase 3 clinical trials including the RedeS study and ReCePI study. The company is pursuing a CE Certificate of Conformity under MDR in the European Union and FDA approval through a planned modular PMA application for the red blood cell system.

• INTERCEPT Blood System—Cryoprecipitation: This segment uses the plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency and to produce pathogen reduced plasma, cryoprecipitate reduced. The company received FDA approval of the premarket approval supplement with respect to IFC in 2020 and has U. S. agreements with certain blood center manufacturing partners. The INTERCEPT Illuminator—LED-based, used in this segment, received CE Certificate of Conformity and CE Marked under MDR in 2025 and is commercialized in a number of countries in Europe and selected countries in other regions around the world.

Cerus Corp holds a leading position in the pathogen reduction technology market for blood products, with the INTERCEPT Blood System being one of the few approved systems for platelets and plasma in major global markets. The company faces competition from entities such as Terumo BCT, Grifols, Octapharma AG, MacoPharma International, and Kedrion Biopharma, which are developing or selling commercial pathogen reduction products, systems, or services. Competitive advantages include the system’s ability to inactivate a broad range of pathogens while preserving therapeutic properties of blood components, integration with existing blood center procedures, and strong intellectual property protection, including 21 issued or allowed U. S. patents and approximately 154 issued or allowed foreign patents as of December 31, 2025.

Cerus Corp serves blood collection organizations, hospitals, universities, and government agencies as its primary customer base, with key customers including the American Red Cross in the U. S. and national blood transfusion services such as the Établissement Français du Sang in France, the National Blood Service in England, and the Japanese Red Cross in Japan. The company also relies on distributors in regions where it has limited direct commercialization capabilities, including certain countries in the CIS, the Middle East, Latin America, and Southeast Asia.

Investment Thesis

▲ Bull case

The company reported first quarter product revenue growth of 24% driven by continued strength in the global platelet franchise and accelerating demand in the US IFC business. This performance indicates that underlying demand for INTERCEPT platelets is expanding beyond historical market growth rates. The group purchasing agreement with Blood Centers of America gives the company access to roughly half of the US blood supply creating a significant expansion runway. Early signs of traction from this agreement including increased activity at existing customers and new agreements to adopt PR platelets suggest the business can sustain double digit revenue growth for the remainder of 2026 and beyond.
The INTERCEPT Fibrinogen Complex franchise showed first quarter revenue growth approaching 90% reflecting increased demand from blood centers manufacturing IFC and deeper utilization within hospitals. Management highlighted that the shift from selling finished therapeutic doses to kit based sales is creating leverage and improving operational efficiency. The transition to kit sales enables the company to partner with blood center sales and marketing channels thereby expanding reach to more hospitals and clinicians. As the company moves toward being fully kit based by the end of the calendar year the underlying volume growth measured in therapeutic dose equivalents remains strongly positive supporting a long term margin expansion story.
Cerus is on track to submit its PMA for the INT 100 illuminator to the US FDA this quarter which represents an important milestone in bringing this technology to the US market. Successful approval and launch of the INT 200 device in 2027 will serve as the foundation for the US platelet and IFC franchises by providing a modern efficient platform for pathogen reduction. The company noted positive receptivity to the illuminator in international markets indicating that similar enthusiasm is likely in the US. This device launch will not only drive new placements but also improve retention of existing customers by enhancing operational efficiency and reducing processing times.
The INTERCEPT red blood cell program continues to advance with the phase 3 RETA study having completed enrollment and expected to read out in the Q4 FY26 providing critical data for an FDA PMA submission. In Europe the CE Mark submission is under review by the French ANSM competent authority with a potential approval timeline in the first half of 2027. Success in the red blood cell program would materially expand the company's clinical impact and open a new large revenue stream beyond platelets and plasma. Given the fundamental need for safe red blood cell transfusions in trauma surgery cancer treatment and chronic transfusion support the upside from regulatory approvals could be substantial and underpins the long term growth narrative.
Operating expenses declined 7% year over year in the first quarter reflecting disciplined control while revenue grew 24% demonstrating operating leverage in the business. Since 2019 operating expenses have increased by less than 3% annually whereas product revenue has grown at a compound annual rate of 18% showcasing the scalability of the model. The company has consistently generated positive non GAAP adjusted EBITDA for eight consecutive quarters and expects to deliver a third consecutive year of positive adjusted EBITDA in 2026. This improving profitability trend combined with a solid cash balance of 80 point 4 million provides a buffer to fund innovation and weather macroeconomic headwinds.

The company reported first quarter product revenue growth of 24% driven by continued strength in the global platelet franchise and accelerating demand in the US IFC business. This performance indicates that underlying demand for INTERCEPT platelets is expanding beyond historical market growth rates. The group purchasing agreement with Blood Centers of America gives the company access to roughly half of the US blood supply creating a significant expansion runway. Early signs of traction from this agreement including increased activity at existing customers and new agreements to adopt PR platelets suggest the business can sustain double digit revenue growth for the remainder of 2026 and beyond.
The INTERCEPT Fibrinogen Complex franchise showed first quarter revenue growth approaching 90% reflecting increased demand from blood centers manufacturing IFC and deeper utilization within hospitals. Management highlighted that the shift from selling finished therapeutic doses to kit based sales is creating leverage and improving operational efficiency. The transition to kit sales enables the company to partner with blood center sales and marketing channels thereby expanding reach to more hospitals and clinicians. As the company moves toward being fully kit based by the end of the calendar year the underlying volume growth measured in therapeutic dose equivalents remains strongly positive supporting a long term margin expansion story.
Cerus is on track to submit its PMA for the INT 100 illuminator to the US FDA this quarter which represents an important milestone in bringing this technology to the US market. Successful approval and launch of the INT 200 device in 2027 will serve as the foundation for the US platelet and IFC franchises by providing a modern efficient platform for pathogen reduction. The company noted positive receptivity to the illuminator in international markets indicating that similar enthusiasm is likely in the US. This device launch will not only drive new placements but also improve retention of existing customers by enhancing operational efficiency and reducing processing times.
The INTERCEPT red blood cell program continues to advance with the phase 3 RETA study having completed enrollment and expected to read out in the Q4 FY26 providing critical data for an FDA PMA submission. In Europe the CE Mark submission is under review by the French ANSM competent authority with a potential approval timeline in the first half of 2027. Success in the red blood cell program would materially expand the company's clinical impact and open a new large revenue stream beyond platelets and plasma. Given the fundamental need for safe red blood cell transfusions in trauma surgery cancer treatment and chronic transfusion support the upside from regulatory approvals could be substantial and underpins the long term growth narrative.
Operating expenses declined 7% year over year in the first quarter reflecting disciplined control while revenue grew 24% demonstrating operating leverage in the business. Since 2019 operating expenses have increased by less than 3% annually whereas product revenue has grown at a compound annual rate of 18% showcasing the scalability of the model. The company has consistently generated positive non GAAP adjusted EBITDA for eight consecutive quarters and expects to deliver a third consecutive year of positive adjusted EBITDA in 2026. This improving profitability trend combined with a solid cash balance of 80 point 4 million provides a buffer to fund innovation and weather macroeconomic headwinds.

▼ Bear case

A significant shareholder has announced intentions to withhold support for the reelection of the board chair and compensation committee chair citing negative returns and share count dilution over the past decade. The shareholder points out that the company's share count has nearly doubled from 101 million to 200 million which has offset business growth and contributed to persistent net losses. Despite shareholder opposition the board has repeatedly sought to increase the authorized share count for equity awards raising concerns about continued dilution. This activism highlights a governance risk where management may prioritize insider compensation over shareholder returns potentially weighing on the stock price.
Government contract revenue increased 11% year over year in the first quarter driven by higher BARDA and Department of Defense related projects but this stream is inherently lumpy and subject to timing of funding cycles. Management noted that full year government related R&D expenses and the corresponding reimbursement are expected to taper this year compared to 2025 creating a potential headwind to total revenue growth. Over reliance on fluctuating government funding could mask underlying commercial performance and lead to volatility in top line results. Investors should consider that any reduction in government reimbursement would directly affect the non GAAP adjusted EBITDA metric that the company uses to showcase profitability.
The company acknowledged that inflationary pressures with shipping and fuel costs foreign currency exchange rates and ongoing tariffs are persistent headwinds that have depressed gross margin to the low fifties range. Although the first quarter gross margin benefited from a less severe impact than initially forecast the trend suggests that margin pressure could continue throughout 2026. Unfavorable foreign currency movements have historically provided a modest boost but can reverse quickly eroding any benefit. If these macroeconomic factors worsen the company may struggle to expand gross margin despite revenue growth limiting the flow through to profitability.
The path to commercialization for the INTERCEPT red blood cell system remains uncertain with the CE Mark submission under review by the French ANSM and no guarantee of approval timeline. Any delay or negative outcome in the European regulatory process would push back revenue generation from this high potential pipeline product. Similarly while the INT 200 PMA submission is planned for this quarter the FDA review process could take longer than anticipated or raise additional questions that delay launch beyond 2027. These regulatory risks represent binary events where failure to obtain approvals would substantially impair the long term growth thesis.
Despite strong growth rates the company remains a single digit share player in both the platelet and IFC markets indicating that substantial upside depends on converting a large untapped customer base. Management acknowledged that they are still early days in the IFC franchise with single digit market share and a tremendous amount of headroom. This low penetration means that success is heavily contingent on the ability to win over key blood center partners such as the American Red Cross and Blood Centers of America. If adoption stalls or if major customers shift to competing pathogen reduction technologies the growth trajectory could flatten quickly.

A significant shareholder has announced intentions to withhold support for the reelection of the board chair and compensation committee chair citing negative returns and share count dilution over the past decade. The shareholder points out that the company's share count has nearly doubled from 101 million to 200 million which has offset business growth and contributed to persistent net losses. Despite shareholder opposition the board has repeatedly sought to increase the authorized share count for equity awards raising concerns about continued dilution. This activism highlights a governance risk where management may prioritize insider compensation over shareholder returns potentially weighing on the stock price.
Government contract revenue increased 11% year over year in the first quarter driven by higher BARDA and Department of Defense related projects but this stream is inherently lumpy and subject to timing of funding cycles. Management noted that full year government related R&D expenses and the corresponding reimbursement are expected to taper this year compared to 2025 creating a potential headwind to total revenue growth. Over reliance on fluctuating government funding could mask underlying commercial performance and lead to volatility in top line results. Investors should consider that any reduction in government reimbursement would directly affect the non GAAP adjusted EBITDA metric that the company uses to showcase profitability.
The company acknowledged that inflationary pressures with shipping and fuel costs foreign currency exchange rates and ongoing tariffs are persistent headwinds that have depressed gross margin to the low fifties range. Although the first quarter gross margin benefited from a less severe impact than initially forecast the trend suggests that margin pressure could continue throughout 2026. Unfavorable foreign currency movements have historically provided a modest boost but can reverse quickly eroding any benefit. If these macroeconomic factors worsen the company may struggle to expand gross margin despite revenue growth limiting the flow through to profitability.
The path to commercialization for the INTERCEPT red blood cell system remains uncertain with the CE Mark submission under review by the French ANSM and no guarantee of approval timeline. Any delay or negative outcome in the European regulatory process would push back revenue generation from this high potential pipeline product. Similarly while the INT 200 PMA submission is planned for this quarter the FDA review process could take longer than anticipated or raise additional questions that delay launch beyond 2027. These regulatory risks represent binary events where failure to obtain approvals would substantially impair the long term growth thesis.
Despite strong growth rates the company remains a single digit share player in both the platelet and IFC markets indicating that substantial upside depends on converting a large untapped customer base. Management acknowledged that they are still early days in the IFC franchise with single digit market share and a tremendous amount of headroom. This low penetration means that success is heavily contingent on the ability to win over key blood center partners such as the American Red Cross and Blood Centers of America. If adoption stalls or if major customers shift to competing pathogen reduction technologies the growth trajectory could flatten quickly.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	182.86 Bn	29.14	4.05	34.05 Bn
2	SYK	Stryker Corp	128.95 Bn	38.64	5.10	14.72 Bn
3	MDT	Medtronic plc	108.31 Bn	22.39	2.98	27.96 Bn
4	BSX	Boston Scientific Corp	68.46 Bn	19.20	3.32	11.03 Bn
5	EW	Edwards Lifesciences Corp	48.25 Bn	2,342.10	7.65	0.60 Bn
6	DXCM	Dexcom Inc	28.35 Bn	30.47	5.88	-
7	GEHC	GE HealthCare Technologies Inc.	28.05 Bn	14.19	1.34	10.14 Bn
8	SNN	Smith & Nephew Plc	26.96 Bn	161.43	4.19	3.18 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password